cardiovascular benefits of glp-1 The conversation around medications is growing, and it goes beyond the number on the scale. According to the American Heart Association, evidence suggests GLP-1s may support heart health and help reduce Semaglutide Shows Secondary Cardiovascular Prevention

*adapted from American Diabetes Association 2024 Standards of Care in Diabetes Available GLP-1 Receptor Agonists (GLP-1 RA) The Table below compares currently available GLP-1RA formulations, notes on their dosing and administration schedule, adjustments and demonstrated cardiorenal benefits

In contrast, in a metanalysis of 12 randomized, double-blind, placebo-controlled trials comprising 3065 of 73 238 participants (4.2%) with diabetes who were using GLP-1 RAs at baseline, SGLT2i reduced the risk of CKD progression in participants both receiving and not receiving GLP-1 RAs [HR 0.65 (95% CI 0.460.94) versus HR 0.67 (95% CI 0.620.72)

While these two dominate the market for now, there are many more GLP-1 treatments in the works, like pemvidutide from Altimmune Inc

Nano-microneedle joint patch, With its unique mechanism of action, it has achieved remarkable results in the treatment of arthritis and bone-related diseases

Many have years of evidence behind them

Protein adequacy often has greater practical impact than isolated micronutrient supplementation